238 related articles for article (PubMed ID: 34776485)
1. Anti-MDA5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine.
Kawamoto S; Abe T; Nagahori K; Yoshino A; Fujii A; Ono Y; Ueda Y; Takeda T
Intern Med; 2022 Jul; 61(13):2007-2012. PubMed ID: 34776485
[TBL] [Abstract][Full Text] [Related]
2. A case of autoimmune pulmonary alveolar proteinosis during the course of treatment of rapidly progressive interstitial pneumonia associated with anti-MDA5 antibody-positive dermatomyositis.
Yatomi M; Akasaka K; Sato S; Chida M; Kanbe M; Sawada H; Yokota I; Wakamatsu I; Muto S; Sato M; Yamaguchi K; Miura Y; Tsurumaki H; Sakurai R; Hara K; Koga Y; Sunaga N; Yamakawa H; Matsushima H; Yamazaki S; Endo Y; Motegi SI; Hisada T; Maeno T
BMC Pulm Med; 2024 Apr; 24(1):170. PubMed ID: 38589870
[TBL] [Abstract][Full Text] [Related]
3. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
Endo Y; Koga T; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Hosono Y; Mimori T; Kawakami A
Medicine (Baltimore); 2018 Jun; 97(26):e11024. PubMed ID: 29952940
[TBL] [Abstract][Full Text] [Related]
4. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
Endo Y; Koga T; Suzuki T; Hara K; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Kawakami A
Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214
[TBL] [Abstract][Full Text] [Related]
6. Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease.
Hata K; Kotani T; Matsuda S; Fujiki Y; Suzuka T; Kiboshi T; Wada Y; Shiba H; Shoda T; Kagitani M; Takeuchi T
Int J Rheum Dis; 2024 Jan; 27(1):e14999. PubMed ID: 38063858
[TBL] [Abstract][Full Text] [Related]
7. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.
Mehta AA; Paul T; Cb M; Haridas N
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33910791
[TBL] [Abstract][Full Text] [Related]
8. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
Osawa T; Morimoto K; Sasaki Y; Matsuda S; Yamana K; Yano R; Uchiyama T; Goto H
Intern Med; 2018 Feb; 57(3):387-391. PubMed ID: 29093381
[TBL] [Abstract][Full Text] [Related]
9. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
10. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review.
Nishi K; Ogura M; Tamai N; Gima M; Ide K; Koinuma G; Kamei K; Ito S
Pediatr Rheumatol Online J; 2022 Aug; 20(1):60. PubMed ID: 35927666
[TBL] [Abstract][Full Text] [Related]
11. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
[TBL] [Abstract][Full Text] [Related]
12. Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Dermatomyositis Presenting as Refractory Gingivitis at the First Clinical Manifestation.
Kawakami E; Uchida T; Iwamoto N; Hara K; Egashira K; Kawakami A
Intern Med; 2024 Jan; 63(1):131-134. PubMed ID: 37197957
[TBL] [Abstract][Full Text] [Related]
13. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
[TBL] [Abstract][Full Text] [Related]
14. Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease - a case report.
De Backer E; Gremonprez F; Brusselle G; Depuydt P; Van Dorpe J; Van Haverbeke C; Goeminne PC; Derom E
Acta Clin Belg; 2018 Dec; 73(6):413-417. PubMed ID: 29287518
[TBL] [Abstract][Full Text] [Related]
15. Early Initiation of Plasma Exchange Therapy for Anti-MDA5
Sasaki N; Nakagome Y; Kojima A; Shimura K; Ishii A; Sugiyama M; Izumi Y; Hirano K; Kurabayashi T; Hosono Y; Yamada C; Sato S
Intern Med; 2024 Jan; 63(2):213-219. PubMed ID: 37225493
[TBL] [Abstract][Full Text] [Related]
16. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
[TBL] [Abstract][Full Text] [Related]
17. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
18. Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease.
Horino T; Inotani S; Nakajima K; Ohnishi H; Komori M; Terada Y
Joint Bone Spine; 2022 Nov; 89(6):105456. PubMed ID: 36108903
[No Abstract] [Full Text] [Related]
19. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
So H; Wong VTL; Lao VWN; Pang HT; Yip RML
Clin Rheumatol; 2018 Jul; 37(7):1983-1989. PubMed ID: 29713969
[TBL] [Abstract][Full Text] [Related]
20. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
